Barrett Elizabeth A. 4
4 · UroGen Pharma Ltd. · Filed Feb 2, 2022
Insider Transaction Report
Form 4
Barrett Elizabeth A.
Chief Executive Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2022-01-31−13,333→ 26,667 total→ Ordinary Shares (13,333 underlying) - Exercise/Conversion
Ordinary Shares
2022-01-31+13,333→ 314,318 total - Exercise/Conversion
Restricted Stock Units
2022-01-31−5,000→ 5,000 total→ Ordinary Shares (5,000 underlying) - Exercise/Conversion
Ordinary Shares
2022-01-31+5,000→ 303,220 total - Sale
Ordinary Shares
2022-01-31$7.58/sh−2,235$16,941→ 300,985 total - Sale
Ordinary Shares
2022-01-31$7.58/sh−5,960$45,177→ 308,358 total - Award
Stock Option (right to buy)
2022-01-31+150,000→ 150,000 totalExercise: $7.72Exp: 2032-01-31→ Ordinary Shares (150,000 underlying)
Footnotes (5)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
- [F2]Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units
- [F3]The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 15,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2021.
- [F4]The reporting person was granted restricted stock units ("RSUs") on January 31, 2021 representing 40,000 ordinary shares. The RSUs vest in three equal annual installments from January 31, 2022.
- [F5]1/3 of the shares underlying the stock options will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025